What is OmniVynt and what problem does it solve?

OmniVynt (by Vynt Intelligence Inc.) is the regulated marketing workspace for life sciences teams. It solves the upstream execution gap — the six weeks between brief and PAAB or MLR submission where 70% of rework costs accumulate. Teams lose time when claims come from multiple sources, evidence is checked late, versions multiply, and issues surface only at submission. OmniVynt fixes this by moving compliance intelligence upstream: from submission-stage bottleneck to brief-stage guardrail. It is advisory-only — Medical Legal Review always retains final authority.

How does OmniVynt reduce PAAB resubmissions?

Based on PAAB 2025 Tag Report, 2026 fee schedule, and modeled agency workflows, OmniVynt is associated with a 44% reduction in PAAB resubmissions — from approximately 1.6 cycles per asset to approximately 0.9 cycles. It does this by catching the three leading causes of resubmissions upstream: label boundary drift (claims exceeding approved indications, ~25% of preventable resubmissions), claim-evidence mismatch (~25%), and citation/reference gaps (~20%). All findings are flagged with the specific PAAB Code clause, PM section reference, rationale, and compliant rewrite options — so teams fix issues before they reach formal PAAB review.

What is ClearVynt and how does the compliance engine work?

ClearVynt is OmniVynt’s glass-box AI compliance intelligence engine. It uses RAG (Retrieval-Augmented Generation) architecture — retrieving from the actual PAAB Code, Product Monograph, and IMC Code — not from statistical inference. Every ClearVynt finding returns five components: (1) Trigger Text — the exact promotional language creating risk; (2) Source Authority — the specific PAAB Code clause and PM section; (3) Rationale — plain-language explanation of the risk; (4) Severity — HIGH RISK / REVIEW / CLEAR; and (5) Rewrite Options — three compliant alternatives (PM-Aligned, Guideline-Aligned, Patient Outcome-Focused). Every finding is verifiable by a Medical Director in 30 seconds. An Approval Probability Score (0–100%) provides a directional indicator, not a regulatory guarantee.

How is OmniVynt different from Veeva Vault PromoMats?

OmniVynt and Veeva PromoMats serve different parts of the workflow. Veeva PromoMats is a downstream Digital Asset Management and MLR system — enterprise-priced ($100K–$500K+ implementation), 8–12 week deployment, requiring the Veeva ecosystem. OmniVynt operates upstream: it is the planning, creation, and pre-validation workspace that feeds PromoMats. Key differences: OmniVynt offers $2,500 Sprint entry (vs $100K+ Veeva implementation), 5-day deploy (vs 8–12 weeks), PAAB-native intelligence (vs generic MLR workflow configured by customer), and glass-box AI where every flag shows the PAAB Code clause and PM reference (vs Veeva's black-box Quick Check Agent scoring). OmniVynt is designed to work alongside PromoMats, not replace it — generating Veeva-compatible export packages from upstream approved assets.

What types of companies is OmniVynt built for?

OmniVynt serves three primary ICP tiers. Tier 1 (primary): Canadian independent pharma marketing agencies (10–200 employees, 150–2,000+ PAAB assets/year — e.g. CPC Healthcare Communications, CTC Medical Communications, Healthwise Creative, FUSE Health, Lemieux Bédard, Lampyon Health Communications). Tier 2 (secondary): Canadian mid-size pharma brand teams (e.g. JAMP Pharma, Knight Therapeutics, Theratechnologies, Searchlight Pharma, BioSyent, Bausch Health Canada, Paladin Labs). Tier 3 (Year 2): US healthcare agencies and pharma brand teams under FDA OPDP scrutiny (e.g. Publicis Health, Omnicom Health, IPG, Havas, Real Chemistry). Also serves commercial-stage biotech, medtech, diagnostics, and AI/digital health teams building MLR infrastructure.

What is the 14-Day Proof Sprint and what does it cost?

The 14-Day Proof Sprint is OmniVynt’s lowest-risk entry mechanism. Teams bring real pharma or life sciences assets, and OmniVynt demonstrates documented ROI before any platform commitment is required. Cost: $2,500–$5,000 one-time (four tiers: Basic, Standard, Professional, Enterprise). Guarantee: 3x ROI or the sprint is free. Zero IT setup required. Deployable within one week of kickoff. Conversion rate: 70–80% of Sprint customers advance to a 90-Day Paid Pilot. Teams that complete a Sprint typically validate $40K–$175K+ in annual savings at 50 assets/year.

Does OmniVynt support PAAB RWE guidance?

Yes. OmniVynt has PAAB's Real-World Evidence (RWE) guidance (introduced February 2024) built into its ClearVynt compliance engine. RWE guidance significantly expanded the complexity of promotional submissions by defining how real-world data can be used to support marketing claims. OmniVynt flags promotional claims that rely on RWE evidence and checks their alignment against PAAB's 2024 RWE standards before assets reach formal PAAB submission — one of the leading causes of increased resubmission rates since 2024.

PlanVynt is OmniVynt’s campaign planning module. It allows regulated life sciences marketing teams to create structured briefs that define: campaign purpose and target audience, intended promotional claims, evidence requirements per claim (PM section, clinical study, RWE reference), regulatory scope (applicable PAAB Code sections, Health Canada PM version, IMC Code), budget assumptions, timeline, brand workspace, and review boundary documentation. PlanVynt creates a structured claim scaffold linked to evidence and regulatory logic before any copy is written — addressing 70% of preventable compliance issues at the brief stage.

Is OmniVynt appropriate for medical device and diagnostics marketing?

Yes. OmniVynt includes MedVynt — a dedicated module for medical device and diagnostics regulatory compliance. MedVynt applies device-specific rules covering intended use, Instructions for Use (IFU) documents, device claims, ISO standards, and FDA 510(k) promotional language. It extends OmniVynt beyond pharma without changing the core platform architecture. This makes OmniVynt suitable for Health Canada Class II+ medical device companies (e.g. NanoTess, RetinaLogik, Fluid Biomed, Intellijoint Surgical) and diagnostics companies (e.g. NiaHealth, Oncoustics, DIAGNOS) building commercial marketing programs.

How does OmniVynt handle bilingual PAAB submissions for Quebec-based pharma?

OmniVynt is designed to support bilingual regulatory workflows important for Canadian pharma advertising, particularly for Quebec-headquartered companies like Bausch Health Canada (Laval, QC), Paladin Labs (St-Laurent, QC), and Knight Therapeutics (Montréal, QC). The platform checks both French and English claims against PAAB Code requirements, Product Monograph content, and IMC standards. Bilingual PAAB submissions add complexity to claim consistency checking — OmniVynt’s evidence-linked claim objects persist across language versions, ensuring regulatory alignment in both official languages.

What is the total cost of PAAB resubmissions OmniVynt helps avoid?

Based on PAAB 2026 fee schedule and modeled agency workflows: 1.6 resubmissions per asset × $1,425 per resubmission cycle × 150 assets per year = approximately $342,000 annual resubmission exposure for a mid-size agency or brand team. OmniVynt’s modeled 44% resubmission reduction translates to approximately $150,480 in avoided resubmission costs annually — before accounting for the time, creative, and delay costs of rework rounds. With PAAB Accelerated Review Options (AROs) costing $2,000+ for 2-business-day review, the cost of getting assets wrong at submission is higher than ever.

Built for regulated life sciences brands and agencies

Stop losing time and marginbefore review begins.

OmniVynt helps regulated pharma, biotech, medtech, diagnostics, and health AI teams catch weak claims, evidence gaps, and avoidable rework before assets reach PAAB, MLR, or FDA/OPDP review.

Book Demo Start 14-Day Proof Sprint

Advisory-only AI · Glass-box logic · MLR retains full authority · Built for regulated marketing teams

53%

Faster content development

44%

Fewer PAAB resubmissions

22.75→10.75

Internal hours per asset

See what OmniVynt catches before review does.

Use a real claim or sample to see where risk, drift, and rework are building upstream before formal PAAB, MLR, or FDA/OPDP review.

OmniVynt · Compliance Analysis Engine

Retrieving from PM and PAAB Code…

HIGH RISK

Compliant Rewrite Options

PM-Aligned

Guideline-Aligned

Patient-Outcome Focused

Advisory-only output. All flags are for illustration purposes. OmniVynt does not approve or certify any commercial material. Medical Legal Review retains full authority.

Make assets stronger before more time is wasted.

OmniVynt helps teams plan claims earlier, develop content against the right source authority, catch risk before submission, and move stronger assets into review. The result is less avoidable rework, cleaner handoff, and better commercial momentum.

Reduce preventable review cycles

Catch the issues that drive resubmissions before assets enter formal review.

Improve claim-evidence control

Link claims to the right source authority early so content starts from a controlled foundation.

Catch PM boundary issues earlier

Surface label drift, fair-balance gaps, and citation problems before they become expensive late-stage rework.

Move assets to review-ready faster

Build and hand off cleaner assets with better documentation and less avoidable friction.

Reduce agency and brand-team rework

Stop rebuilding claims and rechecking evidence late. Work from controlled foundations from the start.

Stronger assets before submission

Move review-ready work forward with clearer context, stronger support, and less avoidable noise.

Most review drag starts before formal review.

The cost is rarely in the review itself. It builds upstream — in weak claims, late evidence checks, fragmented drafting, and versions that multiply before anyone flags the risk. By the time the asset reaches formal review, time is already lost.

1. Fragmented drafting and version chaos

The problem: Claims, evidence, drafts, and comments split across systems create version chaos and weak handoffs.

What changes: One controlled workspace for claims, evidence, and collaboration keeps work aligned before review.

2. Claim and evidence risk caught too late

The problem: Teams are expected to move faster while proving every claim, output, and decision — but risk surfaces too late to fix cheaply.

What changes: Source-verified flags and rewrite guidance strengthen submissions before review, not after.

3. Weaker first-pass quality

The problem: Weak claims, late evidence checks, and incomplete fair balance reduce asset quality before it reaches any reviewer.

What changes: Earlier claim-evidence and fair-balance checks strengthen credibility while helping teams produce stronger review-ready assets.

Sources. ¹ Omnichannel coordination challenge framed around fragmented claims, evidence, drafts, and review inputs in regulated marketing workflows. ² Regulatory pressure reflects PAAB, FDA/OPDP, privacy, AI governance, and internal review standards already referenced across the site. ³ Credible content section reflects OmniVynt’s role in improving claims, statements, and fair balance earlier in development.

See it in action

From brief to submission-ready, in one workflow

Watch how OmniVynt surfaces claim risk, strengthens evidence alignment, and produces audit-ready outputs before formal PAAB, MLR, or other regulated review.

Advisory demo. Illustrative outputs only. Medical, legal, and regulatory teams retain final authority.

Explore the solution Start a sprint

OmniVynt Feature List

A compliance-first planning, collaboration, content, and review platform built for commercial, marketing, medical, and review teams working in regulated environments.

Planning & Project Management

Build strategic project plans in a dedicated workspace. Track metadata, run AI-assisted drafting, manage files, and output printable proposals.

Content & Digital Asset Management

Manage your assets in a central hub. Upload with rich metadata, run version-based reviews, extract text from documents, and integrate with Adobe for supported workflows.

Compliance, Review & Risk Management

Threaded review histories, draft replies, and compliance visibility. Run AI compliance analysis reports on content assets and track issues across the platform.

AI Image Generation & Library

Generate images for your content directly from prompts without worrying about copyrights. Organize your generated and uploaded assets into folders, edit metadata, and store them securely.

Manager & Leadership Tools

Complete oversight of team activities, engagements, venues, and close-outs. Access budget controls, collaboration oversight, and comprehensive compliance tracking.

Core Platform

Secure login, role-based access for cross-functional teams, admin approval workflows, profile management, and a central dashboard with personal activity logs.

AI-Powered Strategy

Generate KPI, resource, and budget suggestions. Summarize project discussions with AI to develop structured strategy within a single workspace.

Collaboration & Chat

Dedicated project chat, threaded discussions, emoji reactions, email invitations, and direct file attachments in the collaboration feed.

Campaigns & Venues

Manage activities, venues, and close-outs. Run risk workflows on every activity, track objectives, attendees, and meeting types.

Document Library

Organizational folder sharing, extract text and summarize documents. Support for PDFs, Word, spreadsheets, and presentation files.

Image Generation

Generate images from prompts, upload your own, and organize into folders with detailed tracking of AI vs uploaded source labels.

Budget Oversight

Track allocations, spend vs allocation, global caps, and activity budgets. Access budget audit logs and policy settings.

Medical Affairs Workspace

Dedicated medical dashboard for scientific materials, medical information, scientific engagement support, HCP oversight, and SOP governance.

Operational Productivity

My Documents, cross-plan activity logs, search, filtering, status badges, shared UI patterns, and downloadable reports.

Built for regulated teams with real review pressure.

OmniVynt fits independent agencies, specialty pharma brand teams, pre-commercial biotech, medtech, diagnostics, and regulated AI-health teams that need stronger assets before formal review begins.

Independent agencies

Lost time, rework, and margin leakage from repeated revision rounds and weak handoffs. OmniVynt reduces that hidden drag before it compounds.

Specialty pharma brand teams

Tighter claim boundaries, denser evidence packages, and narrower patient populations mean wording discipline and upstream control matter more, and mistakes cost more.

Pre-commercial biotech and medtech

New launches create claim pressure, evidence pressure, and review pressure at the same time. OmniVynt helps teams build stronger launch content before the first asset reaches formal review.

Diagnostics and regulated AI-health

Regulated environments with evolving claim standards need upstream control. OmniVynt is designed to complement existing approval systems, not replace them.

Different teams. Same upstream problem.

Every team feels avoidable rework and review drag differently. OmniVynt addresses it at the source.

Agency leaders

Reduce rework and protect margins

Agencies absorb the cost of avoidable rework first — lost time, repeated revision rounds, and margin leakage on preventable cycles. OmniVynt reduces that drag before it compounds.

✓ Fewer preventable revision rounds
✓ Less version confusion across internal, client, and review teams
✓ Proof of value before platform commitment

See the Sprint

Brand & commercial teams

Fewer avoidable cycles before launch

Launch delay and review drag often start upstream. OmniVynt strengthens assets before they enter review so commercial momentum is not lost to preventable rework.

✓ Launch delay from upstream drift and weak claim control
✓ More channels, stakeholders, and asset versions to manage
✓ Cleaner handoff into MLR, PRC, or PAAB

Explore the solution

Medical, legal & regulatory

Stronger assets entering review

Review teams need assets that arrive with claims already checked, evidence attached, and known issues already surfaced. OmniVynt improves what enters review without touching reviewer authority.

✓ Glass-box logic — no black-box recommendations
✓ Cited, reviewable rationale for every flag
✓ Human authority remains fully intact

See Compliance Intelligence

Oncology & specialty brands

Tighter boundaries. Less room for drift.

Narrower indications and denser evidence packages mean claim and evidence discipline matters earlier — and mistakes are more expensive to unwind late in the cycle.

✓ Claim drift beyond approved population, line of therapy, or biomarker
✓ Evidence linkage gaps that surface late and cost more
✓ Higher rewrite cost when issues are caught at MLR or PAAB

Start a sprint

Most review drag starts before formal review.

The cost is rarely in the review itself. It builds upstream — in weak claims, late evidence checks, fragmented drafting, and versions that multiply before anyone flags the risk.

Avoidable rework

Teams rebuild claims, recheck evidence, and fix issues late instead of working from controlled foundations.

Claim and evidence risk

Teams need traceable findings, current sources, and clear rationale before formal review — not after it starts.

Weaker first-pass quality

Claims weaken when evidence is late, loosely matched, or hard to trace into the asset that enters review.

Review drag and launch delay

More channels mean more versions, more stakeholders, and more chances for drift before anyone catches it.

Margin loss from preventable cycles

Most delay happens before submission: finding claims, checking evidence, aligning reviewers, and fixing late issues that could have been caught upstream.

See how OmniVynt fixes this Book a demo

Proven in PAAB workflows · Configurable across life sciences

OmniVynt catches the issues that drive avoidable resubmissions.

Most preventable review friction traces back to three upstream problems. OmniVynt flags them before they become expensive late-stage rework.

Three issues OmniVynt catches early

Label boundary drift

Claims move beyond approved indications, intended use, or cleared parameters.

~25% of preventable resubmissions

Claim–evidence mismatch

Claims lack strong evidence or the right clinical framing.

~25% of preventable resubmissions

Citation & reference gaps

Missing or misaligned sources weaken defensibility in review.

~20% of preventable resubmissions

See how we catch these Test on your assets

The OmniVynt Solution

A Clearer Workflow From Planning to Review

OmniVynt helps regulated life sciences teams plan content and activities, create in one shared workspace, identify compliance issues earlier, and move assets into formal review with clearer communication and sign-off.

Select each stage to see solution outputs

Stage 1 of 4, Brief

Plan content, collateral, activities, events, submissions, and more before creation begins

PlanVynt is the planning workspace for regulated marketing work. It helps teams organize content, collateral, activities, events, submissions, proposals, and other deliverables before creation begins, with clearer direction, shared communication, supporting material, and documented decisions in one place.

Plan content, collateral, activities, events, submissions, and more
Organize supporting material and source references
Align teams on scope, direction, and responsibilities
Keep early communication and decisions in one place

PlanVynt · Campaign Brief · Dupixent Asthma Q4

PM LOADED · TMA Mapped · PAAB Code 2024

HIGH RISK

"cures asthma", off-label claim

PAAB Code 2.10.2 · PM 4.1

REVIEW

"superior to Xolair", head-to-head data required

PAAB Code 5 · Comparative Claims

CLEAR

"reduces severe exacerbations in uncontrolled moderate-to-severe asthma"

Verbatim TMA · PM 4.1

Stage 2 of 4, Build

Create, review, and communicate in one shared workspace

Content Hub brings drafting, comments, revisions, version control, and review context into one place so teams stop losing time across email, calls, meetings, and disconnected files. It helps teams communicate more clearly, collaborate faster, and keep work moving without losing the thread.

Create and review in one shared workspace
Keep comments, revisions, and context in one thread
Reduce communication drag across teams and partners
Maintain version control across content and deliverables

Content Hub · 8 assets · Cross-referencing

Detail Aid v3

PM Aligned

Digital Banner v2

Claim drift detected

Email v1

Review: fair balance

Rep Aid v4

Ready for MLR

Campaign cross-check: "superior" appears in Banner but not supported in Rep Aid, inconsistency flagged · PAAB 5

Stage 3 of 4, Validate

Flag support, wording, and risk issues before formal review

Compliance Intelligence helps teams identify support gaps, risky wording, and potential compliance concerns earlier so fewer problems surface late in the process. It gives teams a cleaner path to review readiness by helping them strengthen work before it reaches formal review.

Surface support gaps and wording concerns earlier
Flag potential risk before formal review
Improve alignment between content and supporting material
Reduce preventable review pushback and rewrite cycles

OmniVynt · Compliance Review · Detail Aid v3

HIGH RISKOff-label implication

Trigger: "helps patients of all ages"

PM 4.1 authorizes adults only. "All ages" implies pediatric use. PAAB 2.10.2.

Rewrite: "indicated for adults 18+ with moderate-to-severe [indication]"

74%

Approval Probability Score

Resolve HIGH flag — est. 92% on resubmission

Stage 4 of 4, Handoff

Move cleaner assets forward with clearer sign-off

Review-Ready Handoff helps teams move assets into formal review with clearer approvals, attributed decisions, timestamps, and version history. That makes sign-off easier to trace, easier to defend, and easier to manage across multiple contributors.

Keep sign-off clear and attributable
Track decisions, timestamps, and version history
Improve handoff into formal review
Strengthen accountability across teams

Compliance Report · Detail Aid v3 · Export Ready

Generated: 2026-04-14 14:32 · Asset: Detail Aid Dupixent Asthma

Flags identified 2 HIGH · 3 REVIEW · 8 CLEAR

Rewrite options accepted 2 of 2 HIGH resolved

Post-rewrite approval score 92%

Export PDF Report

Export Word Dossier

Explore the Full Solution → See a Live Sample Scan

Less rework. Faster launches. Protected margins.

OmniVynt helps teams catch avoidable issues earlier, reduce review drag, and move review-ready work forward faster.

53%

Faster content development

Asset development drops from 22.75 to 10.75 hours. Same headcount, roughly double the throughput without cutting corners.

+112% throughput

44%

Fewer PAAB resubmissions

Catch the flags that cause resubmissions before review begins. Stronger first-pass quality means fewer avoidable cycles.

Cleaner submissions

43%

Compressed review cycles

Internal cycles compress from 25–54 days to 15–28 days. OmniVynt reduces the rounds your team controls so every stage gets faster.

Faster launches

70%

Preventable issues caught early

Label boundary drift, claim-evidence mismatch, and citation gaps account for the majority of preventable resubmissions. OmniVynt flags these upstream.

Preventable errors

Build your business case Start a sprint

Model the cost of avoidable rework in 30 seconds.

Estimate the impact of repeated review cycles, internal drafting time, and preventable submission friction. See where OmniVynt recovers value before making any commitments.

Model ROI Book a demo

Four ways to start with OmniVynt.

Start where it makes sense for your team. Every option is independent, with no required sequence and no lock-in.

Free · On this page

Live demo scan

Single claim · Instant

See the logic before you engage.

+ Enter any claim in the demo above
+ See risk level, source flag, and rationale
+ Glass-box output — no black box
+ No sign-up required

Try the demo

Paid · Contact us

Per-asset scan

Single asset · Full analysis

A complete report on one real asset.

+ Full asset compliance scan
+ Glass-box findings report
+ Source-cited flags + rewrite options
+ No platform commitment required

Most Common

Paid · Refund if no value

14-Day Proof Sprint

3–15 assets · 14 days

Proof of value on your real assets.

+ Prioritized risk report across all assets
+ Evidence-based rewrite options
+ Documented business case + audit docs
+ 60-minute debrief + action playbook

See the sprint

Paid · Custom Quote

Enterprise

Bespoke scope · Ongoing

Embed OmniVynt into your workflow.

+ Full campaign and portfolio review
+ Configured to your PM, SOPs, and markets
+ Train-the-Trainer + compliance playbook
+ Security package + enterprise terms

Request quote

Common questions

What OmniVynt does, where it fits, and how teams usually start.

What is OmniVynt?

OmniVynt helps regulated teams strengthen assets before formal review by improving claims, evidence alignment, and upstream review readiness. It is advisory-only. Medical, Legal, and Regulatory teams retain full authority.

Does OmniVynt replace MLR or approval systems?

No. It improves what enters those systems. OmniVynt is designed to complement existing review processes, not replace them. Reviewer authority is fully retained.

Who is OmniVynt built for?

Regulated pharma, biotech, medtech, diagnostics, and agency teams dealing with review drag, fragmented drafting, and avoidable rework. If your team loses time before formal review begins, OmniVynt is built for that problem.

How quickly can a team start?

Usually within one week once scope and source materials are confirmed. The 14-Day Proof Sprint is the fastest way to validate value on real assets without a platform commitment.

How do teams usually start?

Most start with a demo or a 14-Day Proof Sprint on real assets. The sprint documents where avoidable rework is building in your current workflow and gives your team a practical path to stronger review-ready assets.

Does OmniVynt use black-box AI?

No. OmniVynt is built around glass-box logic. Teams can see what was flagged, why it matters, and what source or rule supports the concern. That visibility is non-negotiable in regulated environments.

OmniVynt Solution Overview

Less Rework. Faster Review Readiness.

OmniVynt is an easy-to-adopt solution for regulated life sciences teams that need to reduce rework, improve accuracy, lower risk, and move assets into formal review with better control.

Easy to Start Less Rework Higher Throughput Lower Risk Shared Sign-Off

Why Teams Need This

Most delay happens before formal review

The problem is rarely one bad asset. It is a broken workflow before formal review: claims and supporting material drift apart, feedback fragments across tools, approvals are hard to trace, and teams spend too much time rewriting work that should have been right earlier.

🔁

Too Much Rework

Teams fix the same issue more than once because context, evidence, and reviewer comments are not in one place.

⚙️

Too Much Friction

Email, calls, comments, and file versions create communication drag and slow every handoff.

⚠️

Too Much Risk

Evidence gaps, unsupported wording, and unclear sign-off increase the chance of preventable review pushback.

📊

Not Enough Visibility

Leadership cannot improve throughput when bottlenecks, rewrite volume, and approval drag stay hidden.

The OmniVynt Solution

A Clearer Workflow From Planning to Review-Ready Handoff

OmniVynt helps regulated life sciences teams plan the work, create in one shared workspace, identify compliance issues earlier, and move assets into formal review with clearer communication and sign-off.

What buyers care about

✓Easy to start
✓Faster review readiness
✓Shared accountability
✓Clearer throughput visibility

How OmniVynt Works

Four connected stages that reduce rework before formal review

PlanVynt helps teams plan the work and align early decisions. Content Hub keeps drafting, comments, communication, and version control in one place. Compliance Intelligence flags issues earlier. Review-Ready Handoff makes approvals and sign-off easier to trace and defend.

🗂️

1. PlanVynt

Plan content, collateral, activities, events, submissions, and more before creation begins

PlanVynt is the planning workspace for regulated marketing work. It helps teams organize content, collateral, activities, events, submissions, proposals, and other deliverables before creation begins, with clearer direction, shared communication, supporting material, and documented decisions in one place.

💬

2. Content Hub

Create, review, and communicate in one shared workspace

Content Hub brings drafting, comments, revisions, version control, and review context into one place so teams stop losing time across email, calls, meetings, and disconnected files.

🚩

3. Compliance Intelligence

Flag support, wording, and risk issues before formal review

Compliance Intelligence helps teams identify support gaps, risky wording, and potential compliance concerns earlier so fewer problems surface late in the process.

✅

4. Review-Ready Handoff

Move cleaner assets forward with clearer sign-off

Review-Ready Handoff helps teams move assets into formal review with clearer approvals, attributed decisions, timestamps, and version history.

See it on your assets

Not sure if it fits your workflow? Show us one real asset.

Bring one anonymised asset and your target market. We’ll show OmniVynt catching risk on your actual claim types — no commitment required.

Book a Demo → See the 14-Day Sprint →

What Changes

What changes when upstream discipline improves

Teams that reduce upstream drift see the impact across every stage: fewer rewrites, cleaner handoffs, and faster movement into formal review.

✓

Less Rework

Fewer avoidable rewrites and fewer issues discovered late.

📈

Higher Throughput

Cleaner handoffs, less communication drag, and fewer stalled review cycles.

🛡️

Lower Risk

Better visibility into support, wording, and approval status.

⏱️

Faster Review Readiness

Teams start from stronger inputs and move cleaner assets into formal review faster.

See it on your own work

Bring a real asset. See the value in the first session.

Show a real asset. See where OmniVynt reduces friction, improves clarity, and shortens the path to review-ready work.

Book a Demo →

How It Works

Plan. Create. Validate. Execute.

See how OmniVynt moves teams from early planning to review-ready submission with less rework.

Plan · PlanVynt Create · Content Hub Validate · OmniVynt Execute · Campaign Manager

The Workflow

Four Connected Stages, One Clear Workflow

From brief through execution, OmniVynt reduces drift and keeps evidence traceable.

Plan

Define claims early, collaboratively

Import your PM at the brief, set guardrails early, and align the team before content starts.

Create

Structured, high-capacity development

Create in one workspace with reusable approved materials, collaboration, and version control.

Validate

Compliance intelligence with defensible audit trails

Flag risk early, suggest rewrites, and strengthen submission readiness with a clear audit trail.

Execute

Submit with confidence at scale

Coordinate execution across teams and export audit-ready reports with every asset.

Content Lifecycle

Scientific evidence

›

Claims framework

›

Content development

›

Compliance review

›

Medical Legal Review / PAAB submission

›

Market execution

✓

OmniVynt enables and strengthens every stage

Moving compliance upstream, and maintaining it throughout, is what drives the 53% development time reduction and 44% fewer resubmissions.

MLR Optimization

Reducing Medical Legal Regulatory Review Bottlenecks

Traditional review can run 5-6 cycles or more. OmniVynt intercepts risk earlier across the five critical MLR categories:

Editorial & Brand Guidelines
Market & Channel Compliance
Regulatory Compliance

Claim Substantiation
Fair Balance

Result: fewer cycles, cleaner submissions, and faster timelines.

Explore the Full Solution → Start a Sprint →

Optimize Your Life Sciences Content

OmniVynt connects evidence, claims, creative development, and MLR readiness in one workflow.

🔬

Scientific Evidence → Claims

Turn complex science into marketing-ready claims.

Generate compliant claims from publications and regulatory sources with linked evidence.

🗂️

Claims Library Creation & Maintenance

Turn approved materials into a living claims asset.

Deduplicate claims, organize variations, and keep every source traceable.

✍️

Creative & Content Development

Accelerate creation with compliant building blocks.

Access claims, disclosures, and citations faster with built-in pre-review validation.

⚖️

Medical, Legal & Regulatory Review

Cut review cycles and increase consistency.

Flag risks across all five MLR categories and standardize review quality across the portfolio.

The Result?

53%

faster content development

44%

fewer resubmissions

1-2

review cycles instead of 5-6

Based on validated OmniVynt benchmarks. Actual results vary by asset complexity, team structure, and internal review protocols.

Already seen enough?

Start with one asset. No IT setup required.

Send us 1–15 assets. We return a compliance risk report, rewrite options, and a documented business case in 14 days.

Start a Sprint → Book Demo →

Deployment & Integration

Start Lightweight. Expand When Value Is Proven.

OmniVynt integrates where you already work, not the other way around. Sprints require zero IT involvement. Platform deployments can shadow your existing approval workflows.

🔗

PromoMats Compatible

OmniVynt operates upstream of PromoMats, improving content quality before it enters the formal Medical Legal Review workflow.

⚡

Zero IT for Sprints

The 14-day sprint requires no technical integration. Send assets, receive reports. No platform access, no IT tickets, no changes to your workflow.

🔮

Shadow Mode & API

Shadow mode deployment available for parallel validation alongside existing review. API available for enterprise clients with existing workflow tools.

Tailorable · Canada-Ready · U.S.-Expandable

Review Claims, Codes and Compliance

Run assets through OmniVynt to identify risk, receive clearer rewrite options, and improve submission readiness.

Run a Compliance Check →

Advisory only, formal review authority remains with your team Canada pharma depth today, broader life sciences configuration supported PIPEDA compliant

Tailorability

Tailored to Your Regulatory Environment, Not a Generic Rule Engine.

OmniVynt adapts review logic based on your product type, claims framework, market, evidence standard, and internal requirements, not a one-size-fits-all ruleset.

📄

Label & Claims Scope

Configured to your Product Monograph, FDA labeling, approved indications, intended use language, contraindications, warnings, and current claim boundaries.

🏥

Product & Category Context

Aligned to the specific evidentiary, risk, and disclosure context for pharma, biotech, medical devices, medtech, diagnostics, AI/digital health, and adjacent regulated offerings.

🏢

Internal Standards & Governance

Incorporates your company or agency workflows, MLR standards, brand frameworks, evidence expectations, risk tolerances, and internal review processes.

🔄

Campaign-Level Consistency

Tracks claims and language across all assets in your campaign, flagging drift and inconsistency omnichannel.

📊

Evidence Standards

Applies your evidence quality standards, including unpublished data policies, citation requirements, and head-to-head data thresholds.

⚡

Actionable Outputs

Outputs are relevant, aligned, and immediately usable, not generic risk warnings requiring further interpretation.

What OmniVynt Identifies

Six compliance domains. Every asset.

OmniVynt evaluates the same categories that generate the highest proportion of preventable PAAB resubmissions.

PM Boundary Risks

Every claim checked against your Product Monograph, indication language, authorized use, contraindications, and dosing boundaries.

Evidence Gaps

Identifies claims lacking sufficient evidentiary support, misrepresenting study data, or citing unpublished data.

Fair Balance Issues

Evaluates whether safety/risk information is appropriately represented relative to efficacy claims per PAAB standards.

Citation Weaknesses

Flags missing, weak, or misrepresented citations, including unpublished data and conference abstracts without adequate qualification.

Superlative Language Risks

Detects phrasing implying superiority without adequate head-to-head data: "best," "leading," "most effective," "first-line."

Cross-Asset Inconsistencies

When multiple assets are submitted, cross-references claim language across all files, identifying drift, contradictions, and inconsistencies.

What Every Flag Is Grounded In

Three source layers. Every review anchored in them.

OmniVynt does not generate generic suggestions. Every output is grounded in the standards that apply to your environment.

Primary Regulatory Source

Market-Specific Codes & Regulations

PAAB and IMC in Canada today, with support for FDA/OPDP requirements, device and diagnostic marketing constraints, and other market-specific commercial or conduct standards as configured for your organisation.

View Example Source →

Primary Claim & Evidence Authority

Approved Labels, Intended Use & Evidence Sources

Health Canada Product Monographs, FDA-approved labeling, intended use statements, cleared indications, validation evidence, and other official claim authorities define what your teams can and cannot say.

View Example Authority →

Internal Governance Layer

SOPs, Review Standards & Brand Rules

Internal SOPs, MLR conventions, quality requirements, reviewer playbooks, partner constraints, and brand guardrails shape how your organisation actually operationalises compliant content development.

Configure for Your Environment →

Example Reviewer-Ready Source Blocks

Advertising & Commercial Codes

PAAB Code of Advertising Acceptance, FDA/OPDP requirements, IMC Code of Ethical Practices, and any other applicable commercial or ethical standards in your markets.

Primary Claim & Label Authorities

Health Canada Product Monographs, FDA-approved labeling and prescribing information, EMA SmPC (where relevant), and all other official claim authorities for your products.

Client-Specific Requirements

Internal SOPs, Medical Legal Regulatory review standards, brand guardrails, therapeutic-area policies, and any market-specific or company-specific rules you need enforced.

Every flag is anchored to the exact governing source and section — with clear rationale and reviewer-ready citations your team can verify in seconds.

Configure OmniVynt for Your Regulatory Environment →

14-Day Proof Sprint

You Are Losing Time and Margin Before Review Even Starts

Most rework in regulated marketing is preventable. It builds upstream — in weak claims, late evidence checks, and versions that multiply before anyone flags the risk. The 14-Day Proof Sprint finds it on your real assets, documents the impact, and shows your team exactly what to fix.

Step 2 of 3 — or start here directly Service-led + AI-augmented No platform commitment required Fee waived if value is not documented

Start Your Sprint → Book Demo

3–15 assets. Fixed scope. Fee waived if value is not documented.

What Your Team Gets in 14 Days

Five deliverables. Ready to use the day we hand them over.

You send 3–15 assets plus briefs. We return everything your team needs to fix the issues, make the business case internally, and move into review stronger.

🔍 Prioritized Risk Report

Human + AI-augmented scan across claims, evidence, and compliance flags — mapped to your guardrails and the governing source for every finding.

✏️ Evidence-Based Rewrite Options

Every high-risk claim flagged with compliant alternatives and source-tied rationale your team can act on immediately.

📊 Documented Business Case

Modeled impact on rounds avoided, margin protected, and timeline compression — built to support internal sign-off.

📋 Audit-Ready Documentation

Exportable reports formatted for internal review, procurement review, or brand leadership — ready to share the day you receive them.

🎯 60-Minute Debrief + Playbook

Live walkthrough of every finding with your team, plus a prioritized action plan for the next asset cycle.

Timeline

1–2

Days 1–2

Kickoff + asset intake

3–10

Days 3–10

Analysis + rewrites

11–13

Days 11–13

Report build + QA

Day 14

Delivery + debrief

What Success Looks Like

“We protected margin on this campaign.”

“We avoided 2+ extra MLR rounds.”

“Assets entered review first-pass ready.”

Typical Outcomes

44%fewer resubmissions (1.6 → ~0.9 cycles)

53%faster asset development

12hrssaved per asset (22.75 → 10.75 modeled)

Based on PAAB 2025 Tag Report, 2026 fee schedule, and OmniVynt workflow benchmarks. Actual results vary by asset complexity and team structure.

Our Guarantee

If we don’t document clear value, the sprint fee is waived.

“The hidden friction was always claim drift and evidence gaps showing up at PAAB submission. OmniVynt catches that upstream, exactly where we needed it.”

MD, Managing Director, Independent Health Agency

We document operational or commercial value based on avoided rework, fewer revision cycles, protected margin, or timeline impact. If that value isn’t documented to your satisfaction, you don’t pay.

How We Document Value

Hours saved × blended team cost
PAAB or MLR resubmission fees avoided
Documented timeline impact for brand and commercial teams
Compliance risk mitigation that is qualitative but material

Payment Terms

New clients: 100% on delivery, net-30
Established clients: net-30 available
No hidden fees
No platform upsell required

Common Questions

Before you book.

Does this change our Medical Legal Review or PAAB process?+

No. The sprint runs alongside your existing workflow. You send assets; we return risk reports and rewrite options. PAAB, MLR, and PRC retain full approval authority — that is non-negotiable and written into every engagement.

What format do assets need to be in?+

Any format your team already uses: PDF, DOCX, PPT, or pasted copy. No special preparation required. We configure analysis to your Product Monograph and applicable ruleset before Day 1.

How quickly can we start?+

Typically within one week of agreement. Day 1 begins with a kickoff call to confirm scope, asset list, and PM loading. The 14-day clock starts from asset submission.

Is there a platform commitment after the sprint?+

No. The sprint is a standalone engagement. If value is demonstrated, we can discuss next steps — but that conversation happens only after you’ve seen results.

What happens to our data?+

All client data is strictly isolated. No cross-client model training — ever. Assets are deleted after analysis is complete. Every engagement includes an NDA. The platform is PIPEDA compliant and no PHI is processed.

How is this different from generic AI tools?+

OmniVynt is glass-box, not black-box. Every flag shows: (1) the exact trigger text, (2) the source authority — a specific PAAB clause, PM section, or IMC principle — and (3) plain-language rationale. Your Medical Director can verify any flag against the source document in 30 seconds.

Is this only for PAAB-bound pharma?+

No. While deepest today in Canadian pharma (PAAB, IMC, Health Canada), the sprint is configurable for FDA/OPDP workflows and across pharma, biotech, medical devices, medtech, diagnostics, and AI/digital health. Tell us your market and product type — we adapt the review logic.

Is This the Right Move Right Now?

The sprint works best in specific conditions.

✓

Good fit right now

Teams with 3–15 live or near-live assets moving toward review
Agencies that need documented value before a broader platform commitment
Commercial teams willing to share anonymized assets, briefs, and review context
Groups that want fast proof of value before changing workflow more broadly

✗

Not the right fit yet

Teams with no active asset flow or live review pressure
Buyers expecting autonomous approval rather than advisory support
Organisations looking for full enterprise rollout before a pilot proves value
Groups unable to share sample materials or key stakeholder context

After the Sprint

Four outcomes. You decide.

At the end of 14 days you have the findings, the business case, and the documentation. What happens next is entirely your call — including doing nothing.

👋

Take the findings and walk away

Everything we delivered is yours to keep — the risk report, rewrite options, and business case. No follow-up required. If the sprint did not document clear value, the fee is waived entirely.

No obligation. No upsell. The work speaks for itself.

📈

Continue with Starter

Expand to a focused 3-asset engagement. Same team, same configuration — pick up where the sprint left off with no restart.

Sprint fee credited in full · 3 assets · Contact us for pricing

Ask About Starter →

🌟

Continue with Core

Full campaign analysis across 5–8 assets. Sprint fee credited in full. Adds a Train-the-Trainer session, compliance playbook, and one fully rewritten asset.

Sprint fee credited in full · 5–8 assets · Contact us for pricing

Ask About Core →

🏛️

Continue with Enterprise

Move directly into a bespoke ongoing engagement — configured to your portfolio, markets, SOPs, and internal standards. Sprint fee credited in full toward your custom quote.

Sprint fee credited in full · Custom scope · Custom quote

Request Enterprise Quote →

🔒

There is no pressure to continue and no automatic renewal. If you choose to move forward to any paid option, the sprint fee is credited in full. If the sprint does not document clear value, the fee is waived. Either way you keep the work and owe nothing more.

Ready to See What’s Actually at Risk?

Tell us your asset types, markets, and current review timeline. We’ll scope the right sprint and get started within a week.

Advisory-only outputs. OmniVynt does not approve, certify, or guarantee acceptance of any commercial material. Medical Legal Review retains full authority. PIPEDA compliant. No PHI processed.

Start Your 14-Day Sprint →

3–15 assets. Fee waived if value is not documented. No platform commitment.

Intelligence

Marketing Intelligence and Security for Regulated Teams

Tailored regulatory references, practical review guidance, and secure configuration built around your products, markets, and internal standards.

Configured Inputs

We don't offer a generic library. We tailor to your needs

📘Reference authority: Your Product Monograph, FDA label, or intended use statement
🧭Internal standards: Your company SOPs, MLR conventions, and brand guardrails
🌐Market-specific codes: PAAB (CA), FDA/OPDP (US), EMA (EU), PMDA (JP), NMPA (CN), and more
⚖️Industry ethics codes: IMC, PhRMA, EFPIA, JPMA, and related standards
🧪Clinical and commercial context: Therapeutic-area policies, evidence standards, and risk tolerances

Tell us your scope. We configure the review logic around it.

Configure Your Review Environment →

Start With What Matters to You

Start by market, product type, or workflow need.

By Market

🇨🇦 Canada: PAAB, IMC, Health Canada DPD
🇺🇸 United States: FDA/OPDP, PhRMA Code, FTC Guidelines
🇪🇺 Europe: EMA, EFPIA, National Competent Authorities
🌏 Asia-Pacific: PMDA (JP), NMPA (CN), HSA (SG), TGA (AU)
🌍 Global: ICH, WHO, cross-border commercial standards

By Product Type

Pharmaceuticals (Rx, OTC)
Medical Devices (Class I-III)
Diagnostics & IVDs
AI / Software as a Medical Device (SaMD)
Digital Health & Wellness

By Workflow Need

Claims substantiation & evidence mapping
Fair balance & risk communication
Comparative claims & head-to-head data
Social media & digital channel compliance
Launch readiness & first-submission quality

External Regulatory Sources

Authoritative references we configure into your review logic.

Canada

PAAB Code of Advertising Acceptance, Health Canada Drug Product Database, and the Innovative Medicines Canada Code.

PAAB Code of Advertising Acceptance → Health Canada Drug Product Database → Innovative Medicines Canada Code →

United States

FDA advertising rules, current OPDP letters, and the PhRMA Code.

FDA Prescription Drug Advertising → FDA Warning & Untitled Letters → PhRMA Code on Interactions with HCPs →

Europe & Global

EMA product information guidance, the EFPIA Code of Practice, and ICH guidelines.

EMA Product Information Guidance → EFPIA Code of Practice → ICH Guidelines →

Need a source not listed? Tell us. We will integrate it.

OmniVynt Guides & Analysis

Practical frameworks built for regulated life sciences teams.

Compliance Strategy

Claims Library Guide: Building a Label-Aligned Foundation

Structure claims so they map directly to your Product Monograph or FDA label, reducing evidence gaps and strengthening first-pass review quality.

OmniVynt Guide · 8 min read

Compliance Strategy

Fair Balance in Digital Channels: A Practical Framework

Adapt risk communication for social, email, and interactive media while maintaining fair balance, clarity, and regulatory alignment.

OmniVynt Guide · 10 min read

Agency & Commercial Ops

The True Cost of Preventable Resubmissions

See how avoidable rework, fee exposure, and margin erosion build across PAAB, FDA, and broader MLR workflows.

OmniVynt Analysis · 6 min read

Agency & Commercial Ops

MLR Handoff Checklist: What to Send, What to Flag

Reduce review friction by sending pre-vetted, source-anchored assets to Medical, Legal, and Regulatory review.

Free Download · PDF

Launch & Expansion

First-Submission Readiness: A Global Launch Primer

Prepare commercial content for simultaneous or staggered market entry without multiplying avoidable review cycles.

OmniVynt Guide · 12 min read

Free Download

Download Free MLR Checklist

Use a practical handoff checklist to improve source anchoring, reduce rework, and prepare stronger assets for formal review.

Open MLR Checklist →

Official Standards Paired to Each Guide

These are the most useful regulatory and workflow references to pair with each OmniVynt guide so the page leads somewhere practical, not to thin placeholder content.

Claims Alignment

Claims Library Guide: Best-Fit Support

Use official PAAB and FDA labeling and promotion standards to keep claims mapped to approved wording, supported by evidence, and easier to defend in review.

PAAB Code of Advertising Acceptance →FDA Promotional Materials Guidance →OPDP FAQs →

Fair Balance

Digital Fair Balance: Best-Fit Support

Use PAAB fair-balance guidance and FDA promotion standards to judge prominence, access to risk content, and whether channel design is distorting benefit-risk balance.

PAAB Fair Balance Guidance →PAAB Fair Balance Weblink Examples →FDA OPDP Office →

Resubmissions & Workflow

Resubmissions Analysis: Best-Fit Support

Pair commercial waste analysis with live enforcement signals and practical MLR workflow references that show where delays, rework, and traceability failures usually begin.

FDA Pharma Warning Letters →MLR Review Process Overview →MLR Efficiency Strategies →

Review Handoff

MLR Handoff Checklist: Best-Fit Support

Use this with practical handoff discipline: clear source packets, version control, flagged sensitivities, and evidence traceability before content enters formal review.

Cross-Functional Handoff Strategies →Review Process Bottlenecks →

Launch Readiness

Submission Readiness Primer: Best-Fit Support

Use official PAAB, FDA, and EMA reference points to align core claims, risk language, market differences, and submission expectations before launch content starts to branch.

PAAB Code →FDA Promotional Submission Guidance →EMA Product Information Requirements →

The point is not to dump regulations onto users. It is to connect each OmniVynt guide to the exact standards and process references that help teams improve claims alignment, fair balance, evidence support, and review readiness.

Your Rules, Your Review

OmniVynt is not a static rule engine. It is a configurable review environment built around your requirements.

Company Policies: Upload your SOPs, brand guidelines, MLR playbooks, or risk thresholds
Market Rules: Select primary and secondary markets; we layer applicable codes and regulations
Product Context: Define product class, indication boundaries, evidence standards, and claim types
Workflow Integration: Align outputs to your existing review tools, approval stages, and documentation needs

We work with you to configure it right.

Schedule a Configuration Session →

Security & Trust

Built for Regulated Environments

OmniVynt is designed for the data handling, privacy, and governance requirements of life sciences teams operating in regulated markets.

🔒

Data Isolation

Every client's data is strictly isolated. No cross-client model training, ever. Your assets are never used to train shared or public AI models.

🇨🇦

PIPEDA Compliant

OmniVynt is built to PIPEDA requirements. For US clients, HIPAA compliance is in scope. Canadian hosting available.

📋

No PHI Processed

OmniVynt handles commercial materials only. No patient-level PHI is ingested or processed at any stage.

🗑️

Data Deletion

All submitted assets are deleted after analysis is complete. No retention of client materials beyond the agreed scope.

📄

NDA on Every Engagement

Every sprint and platform engagement includes a mutual NDA. All discussions and materials are treated as confidential.

✅

SOC 2 Ready

SOC 2 Type II documentation available on request. Certifications confirmed per deployment with audit reports and scope statements.

Request the Security Package

Full data handling policy, HIPAA/GDPR controls, AI governance manifesto, and compliance alignment documentation, available for procurement review.

Request Security Package →

Compliance Strategy

Claims Library Guide Building a Label-Aligned Foundation

Build a usable claims foundation that maps directly to approved label language, evidence, and market rules so downstream drafting is faster and easier to defend.

OmniVynt Guide

8 min read

Claims alignment focus

A good claims library is not a folder of old copy. It is a controlled system that shows which claims are usable, what evidence supports them, where the approved wording comes from, and where each claim can or cannot travel by market, audience, and channel.

What to structure

Claim text linked to exact label or approved source language
Supporting evidence with excerpts, references, and usage notes
Audience and channel limits for each claim
Version history so teams know what changed and why
Comparison flags for superiority, consistency, and fair balance risk

What good looks like

Writers can pull approved claims without guessing
Reviewers can trace each claim back to its source quickly
Teams know which claims are reusable versus net new
Evidence gaps are found before creative work expands
Localization starts from a controlled core rather than scattered files

Official support for this topic

Use these sources when building or validating a label-aligned claims foundation.

PAAB Code of Advertising Acceptance →FDA Promotional Materials Guidance →OPDP FAQs →

Back to Resources →

Compliance Strategy

Fair Balance in Digital Channels

Use a practical framework for judging prominence, access, and readability of risk information across websites, email, social, and interactive media.

OmniVynt Guide

10 min read

Digital channel focused

Fair balance breaks down most often when teams compress benefit claims into the visible surface and push risk language into low-visibility placements. The question is not only whether risk exists somewhere. It is whether the user receives a balanced impression of benefit and risk in the way the channel is actually experienced.

Questions to ask

Is benefit language more prominent than risk language?
Does the design force extra clicks to reach material risk content?
Does the format truncate or soften important limitations?
Would a regulator say the overall impression is balanced?
Are links and disclosures obvious enough for real users?

Channel adjustments

Social: tighten claims and link clearly to risk information
Email: keep risk cues visible before the call to action
Web: avoid burying material safety below long scroll paths
Interactive tools: make risk access persistent, not optional
Video: match spoken or visual benefits with clear risk treatment

Official support for this topic

Use these sources to judge digital fair balance and risk-presentation choices.

PAAB Fair Balance Guidance →PAAB Fair Balance Weblink Examples →FDA OPDP Office →

Back to Resources →

Agency & Commercial Ops

The True Cost of Preventable Resubmissions

Break down how rework, review fees, delay, and lost reviewer attention build when submission quality is weak before formal review starts.

OmniVynt Analysis

6 min read

Commercial ops lens

Most teams can feel review drag. Fewer can show where it starts. The point of this analysis is to expose the avoidable cost building before formal review: time spent rebuilding claims, chasing evidence, reconciling versions, paying for extra cycles, and waiting for already-busy reviewers to recheck preventable issues.

What the cost includes

Unbillable rewrite hours and PM coordination time
External review fees and avoidable cycle extensions
Delayed channel launch or market activation
Reviewer attention pulled toward low-value issues
Margin erosion when revision rounds stack

What to measure

Revision frequency by asset and campaign
Time in queue versus time in active review
Source defects and missing evidence at submission
Reuse rate of approved claims and modules
Wait time between rounds and owner handoffs

Useful external references

Use enforcement and workflow sources together. Regulators show what goes wrong; workflow references show where the operating waste begins.

FDA Pharma Warning Letters →MLR Review Process Overview →MLR Efficiency Strategies →

Back to Resources →

Agency & Commercial Ops

MLR Handoff Checklist What to Send, What to Flag

Prepare a cleaner handoff into Medical, Legal, and Regulatory review with source-anchored materials, version context, and clear risk flags.

Free Download

Checklist format

Review readiness

A strong handoff does not just send the asset. It sends the logic around the asset: what changed, which sources matter, where the sensitivities are, and which items need explicit reviewer attention. That reduces avoidable back-and-forth and makes reviewer time more productive.

Send with the asset

Current claim list with source mapping
Key references and supporting excerpts
Version history and major changes since last round
Market constraints, audience limits, and channel context
Known dependencies on label, policy, or interpretation

Flag before review

Comparative or superiority language
Safety wording and fair balance sensitivities
Any claim not lifted directly from approved wording
Localization changes that could alter meaning
Sections where commercial pressure may overreach the source base

Workflow references

Use these as practical support for handoff discipline, role clarity, and review efficiency.

Cross-Functional Handoff Strategies →Review Process Bottlenecks →

Back to Resources →

Launch & Expansion

First-Submission Readiness A Global Launch Primer

Align the core claim set, evidence package, market differences, and owner roles early so launch content does not fragment into duplicate review effort.

OmniVynt Guide

12 min read

Launch focused

Global launch content slows when each market starts adapting assets from a weak core. Submission readiness means establishing what stays constant, what changes by market, what evidence is acceptable, and who owns the approval path before localization starts to multiply work.

What to align early

Core label language and market-specific variations
Evidence hierarchy and acceptable source set
Localization rules, timing, and accountable owners
Fair balance expectations by market and channel
Submission dependencies that can block launch timing

Where launches stall

Markets adapt assets without a controlled core
Evidence expectations differ but are not mapped early
Risk language changes are left too late
Owner roles blur across brand, regulatory, and agencies
Teams discover regional constraints after creative work expands

Official support for this topic

Use these sources to anchor market-readiness planning before launch materials begin to branch.

PAAB Code →FDA Promotional Submission Guidance →EMA Product Information Requirements →

Back to Resources →

Business Case Calculator

Build the Business Case

Illustrative model for regulated review workflows.

Advisory-only AI

Conservative benchmarks

Built for regulated review workflows

Scenario Model

Model OmniVynt ROI

Based on PAAB 2025 Tag Report and regulated workflow benchmarks. Defaults reflect PAAB averages — adjust to match your team.

Your Operating Profile

Defaults are PAAB 2025 averages. Drag to match your team.

Promotional assets per year 150

1400

Avg. internal rework rounds per asset 3.2

1.06.0

PAAB resubmissions per asset 1.6

0.54.0

Fixed assumptions (PAAB 2025 benchmarks): $159/hr blended labour · 10 hrs/rework round · $167/PAAB resubmission · remediation at $6,000/asset. Remediation rate: 35% of regulated promotional assets require costly hard fixes before approval — redesign, copy overhaul, or re-filing. OmniVynt's upstream compliance screening reduces that to 20%, saving $900 per asset on average. Combined with 34% fewer rework rounds and 44% fewer PAAB resubmissions, OmniVynt delivers an average ~39% reduction in total per-asset cost at PAAB averages. All figures are illustrative expected values — not a guarantee. Actual results vary.

Estimated annual savings

$409,518

Expected value across your asset volume · not a guarantee

$2,730 Avg. saving per asset

$259,740 Labour recovered — 34% fewer rework rounds

$14,778 PAAB fees avoided — 44% fewer resubmissions

$135,000 Remediation saved — 35% of assets need costly fixes at baseline; OmniVynt cuts that to 20%

Book Demo →

We'll walk through your results and show exactly where OmniVynt recovers time, cost, and compliance risk.

Why This Matters

You're Not Just Saving Time, You're Building a Defensible Business Case

Model recovered capacity, lower rework, and faster movement toward review.

Every preventable resubmission costs more than a fee. It also consumes hours and delays downstream activity.

What Your Results Mean

How to Read the Numbers

Metric	What it means
Estimated annual savings	Total gross savings across your asset volume — labour, PAAB fees, and remediation combined
Avg. saving per asset	How much OmniVynt recovers per asset — meaningful from asset one
Labour recovered	Value of rework rounds eliminated — 34% fewer internal review cycles at $159/hr × 10hrs
PAAB fees avoided	44% fewer resubmissions × $167/iteration — direct hard-cost reduction
Remediation savings	Remediation rate drops 35% → 20% — fewer assets needing costly hard fixes at $6,000/asset

Ready to See Your Actual Numbers?

The calculator uses conservative benchmarks. Your 14-Day Proof Sprint documents the working business case on your actual assets.

Compliance risk report on 3-15 real assets
Documented business-case dashboard (your numbers)
PAAB / PM / IMC source citations on every flag
No platform commitment required

Book Demo → Start 14-Day Proof Sprint →

Use the sprint to replace assumptions with your own asset flow, review history, and stakeholder context.

Built for life sciences teams navigating PAAB, FDA/OPDP, EMA, and internal MLR compliance, without the operational drag.

Contact

Start Reducing Rework and Review Friction Today.

Tell us your scope, products, and markets. We'll tailor the demo to your claims, evidence boundaries, and channels, or route you straight to a sprint, security, pilot-partner, or KOL conversation.

📅

Book Demo

Bring 1–2 anonymised assets and your target markets. We'll show OmniVynt working on your actual claim types.

Book Demo →

🚀

Start a 14-Day Sprint

Compliance gaps identified on 3-15 real assets. Business case documented in 14 days.

View Sprint Options →

🔒

Security Package

Data handling policy, HIPAA/GDPR controls, AI governance manifesto, and compliance alignment documentation.

Request Security Package →

🤝

Pilot Partners, Specialty Agencies & Validators

Explore founding pilot participation, workflow feedback, validator conversations, or specialty agency partnerships focused on oncology, hematology, rare disease, and other evidence-dense PAAB-reviewed brands.

Discuss Pilot Fit →

Send Us a Message

We respond within one business day. All information is treated as confidential.

We respond within one business day. All information is treated as confidential. PIPEDA compliant.

What to Expect

Response within one business day
We'll ask about your assets, markets, and current review cycle
Tailored demo using your claim types where possible
No commitment required for the first conversation
All discussions subject to mutual NDA if preferred

"The hidden friction was always claim drift and evidence gaps showing up at PAAB submission. OmniVynt catches that upstream, exactly where we needed it."

MD, Managing Director, Independent Health Agency

FAQ

Frequently Asked Questions

Common questions from commercial, compliance, agency, medical, regulatory, and quality stakeholders across regulated life sciences.

Does OmniVynt replace PAAB, Medical Legal Review, or internal regulatory review?+

No. OmniVynt is advisory-only. It improves what goes into formal review, it does not approve, certify, or guarantee acceptance of any material. PAAB, Medical Legal Review, and PRC retain full authority over all commercial approvals. This is non-negotiable in our contract and on every deliverable.

Is this black-box AI? How do we verify the flags?+

OmniVynt uses glass-box AI with RAG (Retrieval-Augmented Generation). Every flag shows: (1) the trigger text, the exact snippet flagged; (2) the source authority, specific PAAB code clause, PM section, or IMC Code principle; (3) the rationale, plain-language explanation. Your Medical Director can verify any flag in 30 seconds. We don't ask for trust, we show the work.

What rules does OmniVynt support?+

In Canada: PAAB Code of Advertising Acceptance and Health Canada guidance. In the US: FDA prescription drug advertising requirements including fair balance and restrictions on misleading claims. Additional rulesets added per client configuration.

What happens to our data? Is this PIPEDA compliant?+

All client data is strictly isolated, no cross-client model training, ever. Vynt Intelligence retains platform IP; you retain full ownership of your assets. Every engagement includes an NDA. The platform is PIPEDA compliant. No PHI is processed, we handle commercial materials only.

Is PAAB preclearance still required?+

Yes. OmniVynt is upstream preparation, it improves the quality of what goes into required reviews, not a substitute for them.

What's the difference between OmniVynt and PromoMats?+

PromoMats manages commercial material workflow and formal review. OmniVynt is upstream intelligence that improves the quality of what enters any workflow system. OmniVynt is designed to complement, not replace, existing approval platforms.

Are you SOC 2 or ISO 27001 certified?+

Certifications are confirmed per deployment and disclosed in the Security Package. We only claim certifications when audit reports and scope statements exist, confirm current status with our team.

How quickly can a sprint start?+

Typically within one week of signed agreement. Day 1 begins with a kickoff call to confirm scope, asset list, and PM loading. The 14-day clock starts from asset submission.

Still have questions? Talk to the OmniVynt team.

Launch Readiness

Compliance Readiness Before Launch Day

Launches compress every timeline. OmniVynt helps teams build stronger content infrastructure before the first asset reaches formal review.

Launch teams face unique compliance pressure.

A new launch means new claims, new evidence boundaries, and a team learning the review environment in real time. OmniVynt builds that foundation upstream, so your first submission is stronger whether you are launching a drug, device, diagnostic, or AI/Digital Health solution.

Launch Readiness Sprint →

About Us

For Regulated Life Sciences Teams

We are a commercial workflow intelligence platform.

Not a generic compliance checker. A platform that improves how content is planned, created, validated, and executed across regulated life sciences workflows.

What We Are

A commercial workflow intelligence platform for regulated life sciences teams
Deep today in PAAB, IMC, and Health Canada workflows
Relevant across pharma, biotech, medical devices, medtech, diagnostics, and AI/digital health
Configurable for FDA/OPDP, label-based, and client-specific requirements
Advisory-only, Medical Legal Review retains full authority
Glass-box AI, every flag is verifiable
Sprint-first, prove value before commitment

What We Are Not

✗A compliance checker that replaces Medical Legal Review
✗An AI tool that approves content
✗A generic rule engine with no context
✗A replacement for regulatory expertise
✗A workflow tool requiring heavy IT implementation

Start Your Proof Sprint →

Legal

Privacy Policy

How Vynt Intelligence Inc. collects, uses, and protects your information.

Effective date: January 1, 2025 | Last updated: April 12, 2026

1. Who We Are

Vynt Intelligence Inc. ("OmniVynt," "we," "us," or "our") provides commercial workflow intelligence software for regulated life sciences teams. Our principal place of business is in Canada.

2. Information We Collect

Information you provide: When you fill out a form, book a demo, or contact us, we collect your work email address, company name, job role, and any message content you submit.

Usage data: We may collect anonymised, aggregated data about how visitors interact with this website (e.g. pages visited, time on site) using privacy-respecting analytics. We do not use third-party advertising trackers.

Platform data: During a Proof Sprint or platform engagement, you may upload commercial materials (e.g. claims, draft assets). These are processed solely to deliver the agreed service and are deleted after analysis is complete unless otherwise agreed in writing.

3. How We Use Your Information

We use the information we collect to: respond to your enquiry or demo request; deliver and improve the OmniVynt platform and services; communicate about your engagement, account, or sprint; and comply with legal obligations.

We do not sell, rent, or share your personal information with third parties for their marketing purposes.

4. Data Protection & Retention

We implement commercially reasonable administrative, technical, and organisational measures to protect your data. Client data is strictly isolated; no cross-client model training occurs.

Contact information is retained for as long as necessary to maintain the business relationship or as required by law. Uploaded commercial materials are deleted after analysis is complete unless a longer retention period is agreed in your engagement terms.

5. PIPEDA Compliance

We comply with Canada's Personal Information Protection and Electronic Documents Act (PIPEDA). You have the right to access, correct, or request deletion of your personal information. To exercise these rights, contact us at the address below.

6. International Transfers

If you are located outside Canada, your information may be transferred to and processed in Canada. By submitting your information, you consent to this transfer. For clients requiring Canadian-only hosting, this is available upon request.

7. Cookies & Tracking

This website uses only essential cookies required for site functionality (e.g. session state, page routing). We do not use advertising cookies, retargeting pixels, or cross-site tracking technologies.

8. Children's Privacy

OmniVynt is a business-to-business platform. We do not knowingly collect personal information from individuals under the age of 18.

9. Changes to This Policy

We may update this Privacy Policy from time to time. Material changes will be noted by updating the "Last updated" date above. Continued use of the site after changes constitutes acceptance of the revised policy.

10. Contact

For privacy-related enquiries, data access requests, or complaints, please contact us through our Contact page.

Legal

Terms of Use

The terms governing your use of the OmniVynt website and platform.

Effective date: January 1, 2025 | Last updated: April 12, 2026

1. Acceptance of Terms

By accessing or using the OmniVynt website or platform (the "Service"), you agree to be bound by these Terms of Use. If you do not agree, do not use the Service. If you are using the Service on behalf of an organisation, you represent that you have the authority to bind that organisation to these terms.

2. Description of Service

OmniVynt provides advisory commercial workflow intelligence tools for regulated life sciences teams. All platform outputs are advisory only. OmniVynt does not approve, certify, or guarantee acceptance of any commercial material by any regulatory body, review committee, or third party. Final interpretation, approval, and accountability for all compliance and regulatory decisions remain with the appropriate human reviewers within your organisation.

3. No Professional Advice

Nothing on this website or within the OmniVynt platform constitutes legal, regulatory, medical, or professional advice. The information and outputs provided are for informational and workflow support purposes only. You should consult qualified professionals for decisions regarding regulatory compliance, legal matters, or medical claims.

4. Illustrative Metrics & Projections

All metrics, statistics, time savings, cost projections, approval probability scores, and ROI estimates presented on this website or within the platform are illustrative estimates based on modelled workflows, published industry data (e.g. PAAB 2025 Tag Report, 2026 fee schedule), and internal benchmarks. They do not constitute guarantees or promises of specific outcomes. Actual results vary by asset complexity, team structure, review process, and other factors.

5. Intellectual Property

All content, design, code, trademarks, and intellectual property on this website are owned by or licensed to Vynt Intelligence Inc. You may not reproduce, distribute, or create derivative works from any part of this website without prior written consent.

Materials you upload to the platform remain your property. By uploading, you grant OmniVynt a limited, non-exclusive licence to process those materials solely for the purpose of delivering the agreed service.

6. Limitation of Liability

To the maximum extent permitted by applicable law, Vynt Intelligence Inc. and its officers, directors, employees, and agents shall not be liable for any indirect, incidental, special, consequential, or punitive damages, including but not limited to loss of revenue, loss of data, regulatory penalties, or reputational harm, arising from or related to your use of the Service. Our total aggregate liability for any claim arising from or related to the Service shall not exceed the fees paid by you to Vynt Intelligence Inc. in the twelve (12) months preceding the claim.

7. Disclaimer of Warranties

The Service is provided "as is" and "as available" without warranties of any kind, whether express or implied, including but not limited to implied warranties of merchantability, fitness for a particular purpose, and non-infringement. We do not warrant that the Service will be uninterrupted, error-free, or that any outputs will achieve any specific regulatory outcome.

8. User Responsibilities

You are responsible for: maintaining the confidentiality of any account credentials; ensuring that materials you upload do not violate the rights of any third party; and making your own independent compliance and regulatory decisions. You agree not to misuse the Service, including attempting to reverse-engineer, scrape, or access the platform in any unauthorised manner.

9. Governing Law

These Terms shall be governed by and construed in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein, without regard to conflict of law principles. Any dispute arising from these Terms or your use of the Service shall be subject to the exclusive jurisdiction of the courts located in Ontario, Canada.

10. Changes to These Terms

We may update these Terms of Use from time to time. Material changes will be noted by updating the "Last updated" date above. Continued use of the Service after changes constitutes acceptance of the revised terms.

11. Contact

For questions about these Terms, please contact us through our Contact page.

OmniVynt

← Events & Insights Contact Us

Webinar Coming Soon

Why Your Assets Aren’t Review-Ready Before They Reach PAAB or MLR

📅 Date TBD 💻 Live Virtual

Most avoidable delay in regulated marketing does not begin in formal review. It starts earlier — in weak briefs, claim drift, late evidence checks, and assets that look draft-complete but are not truly review-ready. By the time issues surface at PAAB or MLR, the cost to fix them is already high.

This session is for brand teams, agencies, and MLR professionals who want to understand where pre-review breakdown begins and what practical steps can move cleaner work into formal review faster. You will leave with a clearer picture of where your upstream process leaks, what review-readiness actually requires, and which workflow changes have the most immediate impact on resubmission rates and cycle time.

Date and speakers will be confirmed soon.

Webinar Coming Soon

When Claims Move Faster Than Evidence: The Upstream Gap That Causes Most Resubmissions

📅 Date TBD 💻 Live Virtual

Claims drift when evidence is checked too late. The result is avoidable rewrites, weaker reviewer confidence, and assets that reach PAAB or MLR carrying risk that should have been caught upstream. For most teams, this is not a knowledge problem — it is a workflow and timing problem.

This session is for brand teams, agencies, and medical-regulatory professionals dealing with late-stage evidence challenges and resubmission cycles. You will leave with a clearer understanding of where claim-evidence gaps form, how to catch them earlier in your workflow, and what stronger review-readiness looks like before an asset reaches formal review.

Date and speakers will be confirmed soon.

Pilot Partners & KOLs

Founding Pilot Program for Agencies, Early Team Partners, and KOLs

OmniVynt is opening a controlled group of founding relationships. Early participants get preferred terms, closer workflow input, and a chance to help shape the category.

The best early fit is teams with real asset flow, real review friction, and a reason to prove value quickly.

Pharma and Health Agencies

Best fit when revision drag, cross-client complexity, and margin leakage are already visible.

Specialty Brand & Evidence-Dense Teams

Oncology, hematology, rare disease, and other PAAB-reviewed brands where claim boundaries are narrow and upstream drift is costly.

Pilot Partners and KOL Conversations

For operators and experts who want earlier access and a role in shaping the workflow.

Discuss Pilot or Validator Fit →

Broad platform, focused launch: start where review friction and asset flow already matter.

Explore the Solution First → See the Sprint →

OmniVynt — Regulated Marketing Workspace for Life Sciences Teams

Company: Vynt Intelligence Inc.

Brand: OmniVynt™ (platform) · PlanVynt™ · Content Hub™ · ClearVynt™ · MedVynt™

What is OmniVynt?

OmniVynt is the regulated marketing workspace for life sciences teams that need stronger claims, cleaner evidence alignment, earlier issue detection, and better control before formal regulatory review begins. Built by Vynt Intelligence Inc., OmniVynt is not a compliance scanner — it is a full promotional execution system that helps regulated life sciences teams plan campaigns, develop claims, build promotional assets, validate compliance upstream, manage approvals, and hand off cleaner packages into downstream review systems such as PAAB, FDA/OPDP, and internal MLR teams. Advisory-only. Glass-box AI. PIPEDA compliant. AWS ca-central-1.

The Core Problem OmniVynt Solves — The Six Wounds

Regulated life sciences marketing is drowning in preventable rework. The six weeks before a PAAB or FDA submission — the brief, the draft, the evidence map, the claim review — are the most expensive and least controlled part of the process. OmniVynt identifies six wounds driving every buying decision:

The Invisible Six Weeks: Brief to submission is a black box. 70% of costs live here.
The Rework Tax: 1.6× resubmissions/asset × $1,425/cycle × 150 assets = $342,000 annual resubmission exposure.
The Evidence Gap: Claims written in week 1, substantiation gaps found at PAAB or MLR submission.
PM Drift: Product Monograph updated in Q3, campaign approved in Q1 — nobody connected the two.
The Scalability Wall: Senior reviewers cannot scale. Agencies grow accounts but not compliance expertise.
The Coalition Gap: Independent agencies compete with large networks (Klick Health) with none of the built-in compliance infrastructure.

OmniVynt Platform Modules

PlanVynt™: Strategic campaign planning with claim mapping, evidence requirements (PM section, clinical study, RWE reference), regulatory scope (PAAB Code sections, Health Canada PM version, IMC Code), budget, timeline, and brief-stage compliance scaffolding. Captures structure before drafting chaos starts — addresses 70% of preventable compliance issues at the brief stage.
Content Hub™: Multi-file collaborative workspace with version control, PM drift detection, evidence linking, and role-based access. Replaces fragmented email chains and shared drives as the daily system of work for regulated promotional content teams.
ClearVynt™ (Compliance Intelligence Engine): Glass-box AI compliance engine powered by RAG (Retrieval-Augmented Generation) architecture. Retrieves from actual PAAB Code, Product Monograph, and IMC Code. Every finding: Trigger Text (exact language) + Source Authority (PAAB clause + PM section) + Rationale + Severity (HIGH RISK / REVIEW / CLEAR) + Rewrite Options (3 compliant alternatives) + Approval Probability Score (0–100%). Verifiable by a Medical Director in 30 seconds.
MedVynt™: Medical device and diagnostics regulatory layer. Applies intended use, IFU, ISO standards, and FDA 510(k) language checks. Extends OmniVynt beyond pharma without changing the core platform.
Reviews Module: Cross-functional review queue and governance. Role assignments, due dates, overrides, rationale documentation, and approval chains. Makes human review auditable and preserves defensibility.
Issue Log: Canonical record of problems, severity classification, issue status, owner, rationale, timestamp, and resolution tracking. Preserves defensibility and organizational learning across campaigns.

OmniVynt Compliance Intelligence Architecture

ClearVynt uses RAG (Retrieval-Augmented Generation) — not pure language model inference. This means:

Every compliance finding retrieves from the actual PAAB Code, Product Monograph, and IMC Code — not from statistical patterns
Hallucination risk is structurally minimized by grounding all outputs in cited regulatory documents
Claims are verifiable — reviewers can check the exact document and section referenced in any finding
PM updates propagate automatically — when a new Product Monograph version is loaded, active assets are rescanned for drift
Every output is advisory-only — no autonomous approval, no black-box scoring, no claim of regulatory certification

Who Uses OmniVynt — Ideal Customer Profiles

ICP Tier 1 — Canadian Independent Pharma Agencies (Primary Target)

10–200 employee independent Canadian pharma/healthcare marketing agencies. $5M–$50M revenue. 150–2,000+ PAAB assets annually. Pain signal: 1.6+ resubmissions/asset, margin compression, senior reviewer capacity constraints. Named Tier A agencies currently targeted:

CPC Healthcare Communications (ON) — rare disease + oncology, web content compliance, PAAB/HCP review friction
CTC Medical Communications (ON) — Medical Affairs + HCP programs, PAAB/MLR review burden
Healthwise Creative (ON) — 75+ launches, 125+ brands, explicit PAAB regulatory management
FUSE Health Inc. (ON) — pharma + diagnostics + devices, three regulatory frameworks per campaign
Lemieux Bédard (QC) — bilingual PAAB/ASC national health marketing, 100+ employees, regulatory translation load
Lampyon Health Communications (ON) — PAAB-listed, 2,000+ projects, regulated health communications
Maven Medical Marketing — PAAB-listed niche pharma marketing, brand material production compliance
Fisika Inc. (QC) — digital health agency, compliance-intensive workflow

ICP Tier 2 — Canadian Mid-Size Pharma Brand Teams

Canadian pharma companies with 1–5 brands, $100M–$2B revenue. Buying triggers: PM drift causing campaign rework, PAAB rejection on first submission, launch window risk, new regulatory standards. Named accounts:

Knight Therapeutics (Montréal, QC) — pan-American specialty pharma, oncology/rare disease/psychiatry, Notice of Non-Compliance from Health Canada (urgent)
Paladin Labs (St-Laurent, QC) — specialty pharma across pain, urology, dermatology, women's health, CNS
Bausch Health Canada (Laval, QC) — gastroenterology, neurology, dermatology, ophthalmology, bilingual PAAB
Cipher Pharmaceuticals (ON) — dermatology/CNS focus, evidence-heavy claims, increasing PAAB volume
JAMP Pharma — Canadian specialty pharma, multiple therapeutic areas
Theratechnologies — specialty pharma, complex PAAB submissions
Searchlight Pharma — Canadian specialty pharma brand team
BioSyent — Canadian specialty pharma

ICP Tier 3 — Commercial-Stage Biotech

Pre-commercial biotech with no existing MLR infrastructure. Priority: oncology, hematology, rare disease. Named accounts:

Nuvation Bio (ON) — oncology-focused, dense evidence packages, preparing for first commercial launch
Aspect Biosystems (BC) — Series B/partnership expansion, $280M government project, Novo Nordisk partnership
AtomVie Global Radiopharma (ON) — commercial-scale radiopharma with regulatory execution pressure

ICP Tier 4 — Medical Device and MedTech (Health Canada Approved)

NanoTess (Calgary, AB) — NanoSALV catalytic gel, Health Canada authorized 2022, 2026 national distribution rollout
RetinaLogik (Calgary, AB) — portable VR eye-testing device, Health Canada Class II approval, North American launch
Fluid Biomed (AB) — $27M Series A novel device, clinical/regulatory/commercial planning
Intellijoint Surgical (ON) — Ontario funding, 80k+ surgeries globally, commercial scale-up

ICP Tier 5 — Diagnostics and AI/Digital Health

NiaHealth (Edmonton, AB) — annual diagnostic subscription, $8.25M raised, 30%+ M/M growth, provincial expansion
Oncoustics (Toronto, ON) — AI-ultrasound liver diagnostics, DIGITAL supercluster funded, commercializing point-of-care imaging
Simuhealth (Vancouver, BC) — healthcare simulation, $2.6M CAD pre-seed, US expansion underway
DIAGNOS Inc. (Brossard, QC) — AI diabetic retinopathy detection, dual FDA/Health Canada approval pursuit
Visulytix Ltd. (Halifax, NS) — Canadian AI startup, retinal analysis, Health Canada MDL 2025

ICP Tier 6 — US Healthcare Agencies (Year 2)

Following the 2025 FDA enforcement surge (200+ letters, 25-year high). Targets include: Publicis Health, Omnicom Health, IPG, Havas, Real Chemistry — and pharma brands with FDA Untitled Letters.

Competitive Landscape — How OmniVynt Compares

vs. Veeva Vault PromoMats

Veeva PromoMats holds ~80% global market share in life sciences CRM (1,500+ customers). It is the downstream enterprise standard for MLR workflows. OmniVynt is upstream: it operates before PromoMats and generates Veeva-compatible export packages. Key differences: OmniVynt Sprint entry at $2,500 vs Veeva implementation at $100K–$500K+; 5-day deploy vs 8–12 weeks; PAAB-native intelligence vs generic MLR workflow configured by customer; glass-box AI (every flag shows PAAB Code clause + PM reference) vs Veeva's black-box Quick Check Agent scoring.

vs. Revisto

Revisto is a narrow downstream MLR scanning tool focused on claim substantiation. OmniVynt covers the full lifecycle (planning + creation + validation + governance + export). OmniVynt has PAAB Code-specific intelligence with PM section citations; Revisto has minimal published PAAB/OPDP specificity. OmniVynt offers transparent Sprint pricing with 3x ROI guarantee; Revisto pricing is private.

vs. Red Marker

Red Marker is a post-creation brand compliance plugin that integrates with Veeva PromoMats. OmniVynt is the upstream workspace that feeds PromoMats. Red Marker is a generic brand compliance tool; OmniVynt is purpose-built for life sciences MLR with PAAB-native depth.

vs. Generic GenAI (ChatGPT, Claude, Gemini)

Generic generative AI produces very high hallucination risk on medical claims, with no audit trail and significant FDA/FTC regulatory exposure. OmniVynt’s RAG architecture is grounded in actual regulatory documents — all outputs are source-cited and verifiable. Advisory-only posture means OmniVynt never makes autonomous regulatory decisions.

OmniVynt Competitive White Space

OmniVynt occupies the upstream + high regulatory depth quadrant — currently unoccupied by any accessible platform. Veeva is downstream + high depth but enterprise-only. Generic AI is upstream + low depth (hallucination risk). Red Marker and Filestage are downstream + low depth. OmniVynt is the only accessible platform combining upstream workflow positioning with PAAB-native and FDA/OPDP regulatory depth.

Market Size and Growth — Why Now

Pharma Compliance Software: $3.32B in 2025, growing at 11.62% CAGR to $5.74B by 2030 (Mordor Intelligence)
Life Sciences Software Market: $17.69B in 2025, projected $43.19B by 2034 at 10.5% CAGR (Fortune Business Insights)
OmniVynt SAM Canada + US: $133M–$266M ARR at realistic penetration
FDA enforcement surge: 200+ enforcement letters in 2025, highest in 25 years — creates immediate US market urgency
PAAB: 7,700+ reviews annually, increasing complexity from 2024 RWE guidance, Accelerated Review Options (AROs) at $2,000+ for 2-business-day review
Veeva AI Agents launched December 2025 — signals AI-assisted MLR is now industry expectation
50% of biopharma commercial content is now modular — eight of top 10 biopharmas use Vault PromoMats
Cloud pharma software: 65.45% market share in 2024, 17.12% CAGR projected through 2030

OmniVynt Revenue Model and Pricing

14-Day Proof Sprint: $2,500–$5,000 one-time. 3x ROI guarantee or sprint is free. 70–80% conversion to Pilot. Zero IT setup. Deployable within one week.
90-Day Paid Pilot: $2,500–$8,000/month. 50–200 scans/month included. Full platform in shadow mode. 60% conversion to Annual SaaS.
Annual SaaS: $24,000–$96,000+/year. Seat + brand workspace + scan volume pricing. 120% NRR target.
KaaS (Knowledge-as-a-Service): Advisory and regulatory intelligence services complement SaaS.
Year 1 Target: $625K–$1.2M ARR from 20–60 Sprints, 3–5 Pilots, 2–3 SaaS subscriptions + KaaS.
Year 3 Target: $5.7M–$10M+ ARR with enterprise pharma, scaled US presence, medtech vertical.
Client ROI: $40K–$175K+ savings per client at 50 assets/year. Average $1,828 saving per asset (modeled).

Regulatory Frameworks Supported

PAAB — Pharmaceutical Advertising Advisory Board (Canada) — primary, most deeply integrated, native from Day 1
IMC — Innovative Medicines Canada ethical standards and code
Health Canada PM — Product Monograph boundary checking and PM drift detection
PAAB RWE Guidance 2024 — Real-World Evidence promotional compliance
FDA/OPDP — US FDA Office of Prescription Drug Promotion — configurable Year 1, native Year 2
ISO Standards — Medical device promotional compliance (via MedVynt module)
FDA 510(k) — Medical device promotional language checking (via MedVynt)
PIPEDA — Canadian data privacy compliance, AWS ca-central-1 data residency

Health Canada Drug Approvals — Launch Window Targets

OmniVynt tracks Health Canada Notice of Compliance (NOC) events and active review submissions as high-priority commercialization windows. Companies receiving NOC within the past 18 months or currently under Health Canada review represent peak demand for upstream marketing compliance tools. Key therapeutic areas in the current approval pipeline include: oncology, hematology, rare disease, CNS, endocrine therapy, antivirals, and AI medical devices (ophthalmology, neurology, radiology).

Technology and Security

Cloud: AWS ca-central-1 (Canadian data residency)
AI architecture: Glass-box RAG (Retrieval-Augmented Generation) — not statistical inference
Data policy: No PHI at launch. Customer content never used for model training.
Privacy: PIPEDA-aligned
Identity: SAML/OAuth2 SSO, SCIM provisioning (Okta, Azure AD)
Security: Buyer-ready security package available. SOC 2 Type I post-repeatable diligence. SOC 2 Type II Year 2.
Integration: REST API, Veeva Vault PromoMats export, PDF/DOCX native, Snowflake Year 2, Salesforce Health Cloud Year 2
Deploy time: 5 days. Zero IT setup required.

Common Search Queries and Intent OmniVynt Addresses

How to reduce PAAB resubmissions for pharma marketing assets
PAAB compliance software for Canadian pharma agencies
What causes pharma marketing resubmissions at PAAB
FDA OPDP compliance tool for prescription drug advertising
Life sciences marketing compliance AI Canada
MLR review preparation software for pharma brand teams
How to align marketing claims with product monograph
Product monograph boundary check tool for pharma marketing
Fair balance requirements for pharmaceutical advertising Canada
PAAB RWE guidance 2024 real-world evidence marketing compliance
Veeva PromoMats alternative for independent pharma agencies
Pharma marketing workflow software Canada first
Evidence alignment tool for life sciences marketing claims
How to prepare review-ready pharmaceutical marketing assets
Medical device marketing compliance Canada Health Canada
Biotech pre-launch MLR infrastructure software
Health Canada NOC launch marketing compliance
Diagnostics marketing compliance platform Canada
AI digital health marketing compliance PAAB
PIPEDA compliant pharma marketing software AWS Canada
Glass-box AI pharmaceutical compliance
Claims library management regulated pharma
PM drift detection product monograph update campaign
Bilingual PAAB submission software Quebec pharma
FDA enforcement surge 2025 pharma marketing compliance
Canadian pharma agency PAAB workflow software
Oncology drug marketing claims compliance
Rare disease pharma marketing regulatory compliance
Hematology drug advertising PAAB compliance
Sprint to SaaS pharma compliance platform